Protalix BioTherapeutics Inc.

PLX | AMEX

Price Alert Chart Builder DCF Calculator

$2.81

+$0.06 (+2.00%)

Sep 22, 2026, 12:48 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $221.57M

Enterprise Value $203.36M

Beta 0.01

Average Volume 735.97K

Shares Outstanding (Diluted) 82.56M

Shares Change YoY 1.59%

Institutional Ownership 21.12%

Exchange AMEX

ISIN US74365A3095

Price Performance

Price Change 1M 16.0%

Price Change 3M 26.7%

Price Change 6M 27.3%

Price Change YTD 58.0%

Price Change 1Y 34.8%

Price Change 3Y 65.7%

Price Change 5Y 109.9%

1M CAGR (ann.) 11.8%

1Y CAGR (ann.) 47.9%

5Y CAGR (ann.) 13.5%

All-Time CAGR -21.3%

Valuation

PE Ratio 11.96

Forward PE 54.39

PEG Ratio -0.02

Forward PEG -0.14

PS Ratio 2.75

Forward PS 3.30

PB Ratio 3.10

P/FCF Ratio 28.90

P/Adj. FCF Ratio 40.97

P/OCF Ratio 22.92

EV/Sales 2.52

EV/EBIT 8.23

EV/EBITDA 7.74

EV/FCF 26.52

Earnings Yield 8.4%

FCF Yield 3.5%

Adj. FCF Yield 2.4%

Financial Health

Net Cash $27.42M

Total Debt $9.21M

Cash & Short-Term Investments $27.42M

Total Assets $110.34M

Current Ratio 2.94

Quick Ratio 1.91

Debt / Equity Ratio 0.13

Debt / EBITDA 0.35

Debt / FCF 1.20

OCF / Debt 1.08

Interest Coverage 18.63

Altman Z-Score 5.55

Piotroski F-Score 5

Margins & Profitability

Gross Profit Margin 69.2%

Operating Profit Margin 28.9%

EBITDA Margin 32.6%

Net Profit Margin 23.5%

FCF Margin 9.5%

Adj. FCF Margin 6.7%

SBC / Revenue 2.8%

SBC Impact (per share) -29.5%

Returns

Return on Assets 17.2%

Return on Equity 31.6%

Return on Invested Capital 23.3%

Return on Capital Employed 29.5%

Return on Tangible Assets 17.2%

Historical Growth (CAGR)

Revenue CAGR 3Y 6.1%

Revenue CAGR 5Y 10.9%

Revenue CAGR 10Y 9.2%

EPS CAGR 3Y 137.4%

EPS CAGR 5Y 245.1%

EPS CAGR 10Y -26.4%

FCF CAGR 3Y 42321.4%

FCF CAGR 5Y 102.2%

FCF CAGR 10Y 21.8%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 7

EPS Growth Next 3Y N/A

Revenue Growth Next 3Y N/A

Earnings Date Nov 11, 2026

EPS Estimate (next Q) -$0.02

EPS Growth Est (next Q) -166.7%

Revenue Est (next Q) $12.41M

Revenue Growth Est (next Q) -30.5%

Fair Value Estimates

Graham Number $2.15

Graham Upside -21.8%

Lynch Fair Value $5.75

Lynch Upside 109.1%

Price Target $6

Price Target Upside 118.2%

Cash Flow

Operating Cash Flow $9.92M

Free Cash Flow $7.67M

Adj. Free Cash Flow $5.41M

FCF Per Share $0.10

OCF Per Share $0.12

OCF/S Ratio 12.3%

Income Statement

Revenue $80.62M

Gross Profit $55.79M

Operating Income $23.29M

EBITDA $26.28M

Net Income $18.95M

EPS (Diluted) $0.23

Revenue / Employee $356.72K

Profit / Employee $83.83K

Employees 226